Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease - CarboHyde

Oct 10, 2022Tamas Sohajdadrug developmentaging, alzheimers, cyclodextrin, neurodegenerative diseases

Cyclo Therapeutics, Inc. goes for Phase 2b Study of Trappsol® Cyclo™ for treating early Alzheimer’s disease.
See full post…